The experimental lupus drug dapirolizumab pegol, developed by Biogen and UCB, has successfully met its primary goal in a Phase 3 clinical trial, marking a significant step forward in treatment options for the autoimmune disease.

Biogen and Denali Therapeutics have announced they will discontinue their Parkinson's disease therapy after it failed to meet expectations in a mid-stage clinical trial.

Goldman Sachs has announced updated stock price targets for both Figma and Biogen. The financial institution revised Figma's target through 2026 and established a new target for Biogen, influenced by its outlook on Alzheimer's research.

Billionaire investor Steve Cohen reportedly views Biogen Inc. (BIIB) as one of the top biotech stocks for investment.

Analysts are presenting conflicting views on the prospects of several healthcare companies, including CareDx (CDNA), Biogen (BIIB), and Guardant Health (GH).

Biogen has detailed the financial impacts of its Apellis deal, projecting a $120M-$130M other income headwind in 2026 and non-GAAP EPS accretion in 2027.

Financial commentator Jim Cramer provided a range of opinions on various stocks, including calling a CrowdStrike sell-off a mistake and recommending Applied Materials as a "great buy." He also offered advice on Salesforce, AES Corporation, and other companies.

ASIC has released its Q4 2025 earnings transcript, while Biogen (BIIB) has published its Q3 2025 earnings transcript. These documents provide detailed financial information for the respective companies.

Wells Fargo has upgraded Biogen's stock rating to Overweight, raising questions about a potential resurgence in the company's Alzheimer's drug development.

An Innsbruck-based startup, ParaStruct, is developing innovative low-carbon building materials by utilizing mineral and biogenic waste products, as part of a regular startup feature in collaboration with i2b.

Biogen has indicated that its first-quarter net income per share will be negatively impacted by approximately $0.19.

Apellis Pharmaceuticals (APLS) stock has reached a two-year high, showing a 140% upside following its merger with Biogen.

Biogen is making a strategic move into the rare disease market with a $5.6 billion acquisition of Apellis Pharmaceuticals, aiming to expand its portfolio in this specialized area.

Biogen and Alteogen have finalized a new licensing deal specifically for injectable products, further expanding their pharmaceutical portfolios.

An analysis suggests that Biogen (BIIB) is an attractive holding for long-term investors.

Biogen is facing an antitrust probe in Italy concerning its rivalry with Sandoz over multiple sclerosis drugs. The investigation will examine potential anti-competitive practices in the pharmaceutical market.

Analysts on Wall Street are currently evaluating whether there is a bullish sentiment surrounding Biogen's stock, considering various market factors and company performance.

Biogen announced its decision to move an experimental Alzheimer's drug into a late-stage trial, despite the drug missing its primary endpoint in mid-stage clinical trials. The company is proceeding with the drug's development despite the initial disappointing data.

The U.S. Food and Drug Administration (FDA) has extended its review period for Biogen's Alzheimer's injection, Leqembi, delaying a decision on its approval.

Biogen stock experienced a positive performance on Wednesday, making it a winner in the market.

Biogen adjusted its full-year earnings outlook downwards, citing the impact of business development activities on its financial projections.

UBS has upgraded its rating for pharmaceutical company Biogen to 'Buy,' setting a new price target of $225. The investment bank suggests that the next 12 months could see a series of pipeline catalysts for the stock, making it an attractive investment relative to its peers.

An earnings preview has been released for Biogen, outlining expectations ahead of the company's upcoming financial report.

Analysts on Wall Street issued their top recommendations for several major companies on Monday, including Nvidia, Apple, Tesla, Microsoft, and Amazon.

Zacks.com featured highlights include Biogen, TE Connectivity, and ZTO Express (Cayman), indicating notable performance or analysis for these companies.

Piper Sandler has raised Biogen's stock rating to Overweight, citing the company's acquisition of Apellis as the reason for the upgrade. This reflects a positive financial outlook for Biogen.

Morgan Stanley has increased its price target for Vertex Pharmaceuticals to $612 from $596, indicating a positive outlook for the company's stock.

Following a significant $5.6 billion buyout, Biogen is now redirecting its strategic focus towards early-stage assets in its portfolio.

Apellis Pharma's stock has seen a significant surge following a deal with Biogen, leading investors to question if it's too late to capitalize on the APLS stock rally.

Biogen has secured approval from the FDA for a higher dosage of its drug designed to treat a genetic disorder.

An analysis evaluates whether Biogen's stock (BIIB) is currently outperforming the broader healthcare sector, examining its market performance.

Three doctors and a science journalist are facing a legal dispute after receiving a claim from the Endobiogenics Institute regarding a social media post about endobiogenics.

Auris Energia has provided an updated timeline for the Säkylä biogas plant, with production now slated to begin in the summer of 2029, following delays caused by an additional investment in a biogenic carbon dioxide capture facility.

Immunic, a biopharmaceutical company, has appointed Mike Bonney, a veteran from Biogen and Cubist, as its new board chair. The appointment comes ahead of a key multiple sclerosis (MS) trial readout.

Several prominent stocks are exhibiting significant movements in premarket trading, with some experiencing notable gains and others gapping down.

An analysis provides insights into the performance and outlook of several pharmaceutical giants, highlighting Bristol Myers' legacy boost, Biogen's positive prospects, and Regeneron's uncertain future.

UBS has upgraded its rating for Biogen Inc., anticipating positive developments from the company's drug pipeline that could drive future growth.

This article summarizes Wednesday's key research calls from Wall Street analysts concerning companies such as Abbott Laboratories, Airbnb, Biogen, and others.

Biogen has announced plans to purchase the rights to an immune disease drug for the Chinese market. The deal is valued at up to $850 million.

Italy and Tunisia have joined forces to launch Biogen4Med, a new initiative aimed at fighting cancer through precision medicine.

Zacks.com has released its featured highlights, recommending investments in Biogen, TE Connectivity, and ZTO Express (Cayman).

Biotech firm Biogen is projected to maintain growth despite anticipated lower royalties for its drug Ocrevus after patent expiration, supported by its development of other medicines, according to Piper Sandler.

Biogen's stock saw a sharp drop on Monday, leading to investor concerns and analysis of the reasons behind the decline.

Biogen has announced the acquisition of Apellis for $5.6 billion, a move aimed at strengthening its pipeline for rare disease treatments.

Biogen has received approval from the U.S. Food and Drug Administration for its high-dose Spinraza regimen, a treatment for spinal muscular atrophy.

The energy sector is focusing on biogenic CO2 as a potential new fuel source to help decarbonize air transportation, exploring its capabilities as a byproduct.

Wall Street analysts are providing target price analyses for Biogen stock.